Skip to main content

Head Genetics is a biotech company established to develop saliva-based concussion assessment device.

Head Genetics is outfitted with various assays that can detect biomarkers in a multitude of health conditions, initially targeting Concussion.

Saliva-based assessments garnered a lot of attention during the most recent pandemic. As mentioned, multiple times in the media.

EASY TO USE & NON-INVASIVE
Exceeds current concussion diagnostic protocol by bringing results closer to the individual.

INEXPENSIVE & FAST
Results obtained without expensive, lab or hospital-based equipment allowing individuals, clinicians and other healthcare providers to make virtual real time decisions.

PROJECT
Concussion Assessment Device

PROJECT STARTED
2013

MATERIALS
BPA Free, FDA approved, premium materials 

Head trauma happens everyday to millions

Millions of brain-related injuries contribute to an unknown number of future diseases, yet we have no way to measure for definitive trauma or qualify the trauma experienced.

WORLDWIDE STATISTICS
The TBI injury diagnostic global market is approaching $1.75 billion & is expected to reach $3 billion by 2028.

70

million cases of concussion annually

40

of concussive events remain undiagnosed

The current protocol for assessing brain trauma is indeterminate and slow. That ends now.

The problem

Brain-related injuries contribute to an unknown number of future diseases, yet we have no way to measure for definitive trauma or qualify the trauma experienced

Concussion

Head Genetics saliva-based over the counter (OTC) assay device will be a game changer for the at home user and clinicians knowing that the leading cause of mTBI is caused by falling. 

“the public is holding professional leagues accountable”

Recent viral media of player injuries have fans and viewers calling for complete protocol overhauls